Spinal anesthesia, born in the late 19th century with August Bier’s pioneering work in 1898, represents a major innovation in anesthesiology [1]. The evolution of local anesthetics (procaine in 1905, lidocaine in 1943, bupivacaine in the 1960s) and the introduction of “pencil-point” needles in the 1980s facilitated its widespread adoption [2]-[4]. Today, spinal anesthesia represents the technique of choice for more than 95% of elective cesarean sections [5].

Post-spinal hypotension constitutes the most frequent complication in obstetrics, occurring in 70% - 80% of cases compared to 20% - 30% in general surgery [6]. This particular vulnerability of pregnant women results from specific anatomophysiological modifications: aortocaval compression by the gravid uterus, reducing venous return by 30% - 50%, increased sensitivity to local anesthetics, and pregnancy-related cardiovascular adaptations [7]-[9].

Maternal hypotension compromises uteroplacental perfusion, exposing the fetus to hypoxia and acidosis [10]. It manifests clinically through nausea, vomiting, and in severe cases, maternal loss of consciousness [11].

Ephedrine has long dominated management due to its mixed α and β-adrenergic action [12]. However, the landmark study by Cooper etal. (2002) demonstrated its responsibility in fetal acidosis, initiating a paradigmatic shift [13]. Phenylephrine then emerged as a safer alternative, but its pure vasoconstrictor action can induce reflex bradycardia [14].

Norepinephrine, an endogenous catecholamine combining predominant α1-adrenergic activity with moderate β1-adrenergic effect, presents a theoretically optimal profile [15]. Recent studies confirm its efficacy with better hemodynamic stability [16][17]. A 2024 systematic review and network meta-analysis by Zhang etal. demonstrated norepinephrine’s superior hemodynamic profile compared to both ephedrine and phenylephrine in obstetric populations, with improved maternal outcomes and equivalent neonatal safety [18].

Despite favorable evidence, questions persist regarding the optimal administration modality of norepinephrine: curative boluses versus prophylactic continuous infusion. Direct comparative data with ephedrine is conspicuously sparse. Our study aims to fill these gaps by comparing three strategies: bolus ephedrine, bolus norepinephrine, and continuous norepinephrine infusion, to determine the optimal therapeutic approach.

Prospective analytical study conducted from February to June 2025 at the Department of Maternity Intensive Care, University Hospital Mother and Child Harouchi, Ibn Rochd, Hassan II University, Casablanca. The protocol was approved by the institutional ethics committee with informed consent from all participants (Reference: EC-2025-02-15).

Inclusioncriteria: Adult patients (≥18 years), singleton pregnancy at term (≥37 weeks), ASA I-II, elective cesarean section under spinal anesthesia, post-spinal hypotension (SBP < 90 mmHg or decrease >30% from baseline values).

Exclusioncriteria: Cardiovascular pathology, contraindication to spinal anesthesia, emergency cesarean section, vasopressor allergy, refusal to participate, multiple pregnancy, preeclampsia.

Randomizationsequencegeneration: Computer-generated randomization sequence using permuted blocks of varying sizes (3, 6, 9) created by an independent statistician using R software (version 4.3.0). The randomization list was stratified by maternal age (<30 vs ≥30 years) to ensure balanced allocation across age groups and minimize potential confounding effects.

Allocationconcealment: Allocation concealment achieved through sequentially numbered, opaque, sealed envelopes prepared by research personnel not involved in patient recruitment or clinical care. Envelopes were stored in a locked cabinet and opened only after patient enrollment, informed consent, and completion of baseline measurements by the attending anesthesiologist. This process ensured that neither the investigators nor the clinical staff could predict treatment assignment.

Aprioripowercalculation: Based on pilot data from our institution showing 70% efficacy with ephedrine versus 90% with norepinephrine for hypotension correction, with α = 0.05 and β = 0.20 (80% power), the calculated sample size was 51 patients per group using Fisher’s exact test. Accounting for a 10% dropout rate and potential protocol violations, 57 patients were recruited per group, totaling 170 patients. This sample size provides adequate power to detect a clinically meaningful difference of 20% between groups for the primary endpoint.

Standardized spinal anesthesia in sitting position (L3-L4, L4-L5, or L5-S1) with 25 25-G pencil-point needle (Whitacre, BD Medical). Solution: hyperbaric bupivacaine 0.5% (10 - 12.5 mg) + fentanyl 25 µg. Positioning in the supine position with 15˚ left lateral tilt using a standardized wedge. Standard monitoring: ECG, SpO₂, NIBP every 2 minutes, continuous cardiac rhythm monitoring for arrhythmia detection throughout the procedure.

Baselinebloodpressuredefinition: Baseline blood pressure was defined as the mean of three consecutive measurements taken 5 minutes apart in the pre-operative holding area, with the patient in supine position with left lateral tilt, after 10 minutes of rest. All measurements were performed using the same automated oscillometric device (Philips IntelliVue MP70) with an appropriate cuff size, calibrated daily according to manufacturer specifications.

GroupI(n=57): Ephedrine 5 mg/mL (Aguettant, France), bolus 3 - 6 mg IV every 2 minutes until SBP restoration (maximum cumulative dose 30 mg).

GroupII(n=56): Norepinephrine 16 µg/mL (diluted from 1 mg/mL ampoules, Aguettant, France), bolus 8 - 16 µg IV according to hemodynamic response, repeated every 2 minutes as needed.

GroupIII(n=57): Norepinephrine 16 µg/mL in prophylactic continuous infusion via syringe pump (initial rate 8 mL/h ≈ 5 µg/kg/h), started immediately after spinal injection, adjusted to maintain SBP ≥ 90% of baseline values.

Hemodynamicvariables: HR, SBP, DBP, MAP recorded at times T0 (pre-spinal baseline), T1 (5 minutes post-spinal), T2 (fetal delivery), T3 (skin closure).

Neonatalvariables: Apgar scores (1, 5, 10 minutes), birth weight, umbilical cord blood gas analysis, pediatric evaluation.

Primaryendpoint: Hypotension correction efficacy, defined as restoration of SBP > 80% baseline values within 5 minutes of the first vasopressor administration. The 5-minute window starts from the moment of first drug injection (time zero = first vasopressor bolus administration).

Secondaryendpoints: Hemodynamic stability (coefficient of variation of SBP), maternal tolerance (nausea, vomiting, satisfaction score), neonatal adaptation (Apgar scores, cord blood pH), and total vasopressor consumption.

Safetymonitoring: Continuous cardiac rhythm monitoring throughout the procedure using 3-lead ECG for detection of arrhythmias (atrial fibrillation, ventricular ectopy, bradycardia < 50 bpm, tachycardia > 120 bpm), hypertensive episodes (SBP >160 mmHg), and clinical assessment of other catecholamine-related adverse events (tremor, anxiety, peripheral vasoconstriction).

Statistical analysis was performed using SPSS version 26.0 (IBM Corp., Armonk, NY). Quantitative variables expressed as mean ± standard deviation or median [interquartile range] according to distribution. Normality was assessed using the Shapiro-Wilk test. Comparisons between groups were performed using one-way ANOVA with post-hoc Tukey tests for normally distributed variables, Kruskal-Wallis test with Dunn’s post-hoc for non-parametric data, and Chi-square or Fisher’s exact test for categorical variables. The significance threshold set at p < 0.05. Intention-to-treat analysis performed for all randomized patients.

Demographic analysis reveals satisfactory homogeneity between the three therapeutic cohorts. Mean maternal age was 28.4 years ± 5.2 years (Group I), 29.1 years ± 4.8 years (Group II), and 28.7 years ± 5.1 years (Group III), with no statistically significant difference (p = 0.742). Pre-pregnancy body mass index remained comparable between groups (24.8 kg/m² ± 3.1 kg/m² vs 25.2 kg/m² ± 2.9 kg/m² vs 24.6 kg/m² ± 3.3 kg/m², p = 0.658).

Maternal parity showed no inter-group disparity, with a proportion of primiparous women of 52.6% (Group I), 51.8% (Group II), and 54.4% (Group III). Gestational age at the time of surgical intervention was homogeneous: 38.9 weeks ± 1.2 weeks of amenorrhea for the entire study population (Table 1).

Table 1. Baseline hemodynamic parameters at T0 (pre-spinal).

Data expressed as mean ± standard deviation. BP: Blood Pressure. No significant differences between groups (p > 0.05), confirming successful randomization and hemodynamic equivalence at baseline.

3.2.1. Heart Rate Evolution

Chronological analysis of heart rate reveals diametrically opposed evolutionary profiles according to the vasopressor strategy employed. Group I (ephedrine) presents progressive and sustained tachycardia, with heart rate peaking at 133.7 beats ± 6.3 beats per minute at time T2 (fetal delivery), representing a 71% increase from baseline values (p < 0.001) (Figure 1).

Figure 1. Perioperative heart rate evolution by therapeutic group. Curves represent means ± standard error. The hatched zone delimits tachycardia (>100 bpm). Asterisks indicate statistical significance (***p < 0.001) between groups at times T1 and T2.

Conversely, Groups II and III (norepinephrine) maintain remarkable chronotropic stability. Group II displays a heart rate of 87.5 bpm ± 4.7 bpm at T2, while Group III maintains a rate of 85.3 bpm ± 3.8 bpm, representing variations of less than 10% from reference values. This inter-group difference reaches major statistical significance (p < 0.001) at times T1, T2, and T3.

3.2.2. Systolic Blood Pressure Dynamics

Evolution of systolic blood pressure constitutes the principal discriminating parameter of therapeutic efficacy. Group I presents profound and prolonged hypotension, with systolic pressure dropping to 80.5 mmHg ± 3.8 mmHg at time T1, representing a 37% decrease from pre-anesthetic values. Blood pressure recovery proves slow and incomplete, reaching only 95.2 mmHg ± 4.5 mmHg at T2 (Figure 2).

Figure 2. Perioperative systolic blood pressure evolution. Curves represent means ± standard error. The hatched zone delimits hypotension (<90 mmHg). The dotted line indicates the normal blood pressure target. Statistical annotations show significant differences between groups.

Group II demonstrates exceptional blood pressure recovery capacity, with rapid restoration to 126.2 mmHg ± 1.3 mmHg by T2, even exceeding baseline values. This therapeutic performance translates to a highly significant difference compared to Group I (p < 0.001).

Group III, benefiting from the prophylactic approach, maintains a systolic pressure of 118.5 mmHg ± 8.2 mmHg at T1, thus limiting the amplitude of the initial blood pressure drop. This preventive strategy proves statistically superior to both other approaches (p < 0.001).

3.2.3. Mean Arterial Pressure and Tissue Perfusion

Analysis of mean arterial pressure, the determining parameter of tissue perfusion, confirms the observed therapeutic hierarchy. Group I presents critical mean hypotension, with values of 58.3 mmHg ± 2.9 mmHg at T1, potentially compromising uteroplacental perfusion (Figure 3).

Group II effectively restores mean pressure to 89.5 mmHg ± 2.1 mmHg at T2, ensuring adequate tissue perfusion. Group III maintains a mean pressure of 82.9 mmHg ± 10.6 mmHg at T1, preserving peripheral perfusion from the post-spinal phase.

Evaluation of therapeutic efficacy, defined by restoration of systolic blood pressure to more than 80% of baseline values within five minutes following the first vasopressor administration, reveals manifest superiority of norepinephrine-based protocols (Figure 4).

Figure 3. Perioperative mean arterial pressure evolution. Curves illustrate mean blood pressure dynamics with error zones. The hatched zone indicates critical hypotension (<65 mmHg). The dotted line represents the normal mean arterial pressure target.

Figure 4. Therapeutic efficacy distribution by treatment group. Box plots (whisker plots) present median, quartiles, and outliers. Dotted lines indicate means. Statistical annotations demonstrate significant differences (***p < 0.001).

Group III achieves therapeutic efficacy of 94% (95% CI: 89% - 97%), followed by Group II with 89% (95% CI: 83% - 93%), while Group I achieves only 68% efficacy (95% CI: 60% - 75%). This inter-group difference presents major statistical significance (p < 0.001), confirming the pharmacological superiority of norepinephrine.

Evaluation of immediate neonatal adaptation, measured by Apgar scores, reveals no statistically significant difference between therapeutic groups. This reassuring observation confirms the fetal safety of the three vasopressor strategies studied (Figure 5).

Figure 5. Distribution of neonatal Apgar scores at 1 and 5 minutes. Box plots (whisker plots) illustrate the complete score distribution with median and mean. The absence of a significant difference confirms equivalent neonatal safety of the three therapeutic approaches.

Apgar scores at 1 minute were 8.2 ± 0.8 (Group I), 8.4 ± 0.7 (Group II), and 8.3 ± 0.8 (Group III), p = 0.456. At 5 minutes, scores reached 9.1 ± 0.6, 9.3 ± 0.5, and 9.2 ± 0.6, respectively, p = 0.312. These results attest to the absence of deleterious impact on immediate neonatal cardiorespiratory adaptation.

Analysis of maternal tolerance reveals a differential adverse effect profile according to therapeutic strategy. Group I presents a high incidence of nausea (42.1%) and vomiting (28.1%), symptoms directly correlated with prolonged hypotension and excessive tachycardia.

Groups II and III display significantly superior maternal tolerance, with nausea incidences of 12.5% and 8.8%, respectively (p < 0.001 vs Group I). Vomiting incidence also remains reduced: 7.1% (Group II) and 5.3% (Group III) versus 28.1% (Group I), p < 0.001.

Maternal satisfaction, evaluated by visual analog scale (0 - 10), proves significantly superior in norepinephrine groups: 8.7 ± 1.2 (Group II) and 8.9 ± 1.1 (Group III) versus 6.8 ± 1.8 (Group I), p < 0.001.

Continuous cardiac monitoring revealed no episodes of clinically significant arrhythmias in any group. No cases of atrial fibrillation, ventricular ectopy, or severe bradycardia (<50 bpm) were observed. No cases of severe hypertension (SBP > 160 mmHg) were documented. One patient in Group III experienced transient mild hypertension (SBP 145 mmHg), which resolved spontaneously without intervention within 3 minutes.

Clinical assessment for other catecholamine-related adverse events showed no cases of tremor, anxiety, or clinically significant peripheral vasoconstriction requiring intervention.

Table 2. Summary of principal statistical results.

Data expressed as mean ± standard deviation or percentage. Different letters (a, b, c) indicate statistically significant differences between groups (p < 0.05) according to Tukey post-hoc tests. HR: Heart Rate; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MAP: Mean Arterial Pressure; VAS: Visual Analog Scale; AE: Adverse Events.

Post-spinal hypotension in cesarean section results from a complex interplay of anatomophysiological factors specific to pregnancy and the pharmacological effects of neuraxial blockade [6][7]. The primary mechanism involves sympathetic blockade extending from T4 to S5 dermatomes, causing arterial and venous vasodilation with subsequent reduction in systemic vascular resistance and venous return [8].

In pregnant women, this physiological disruption is amplified by pregnancy-specific cardiovascular adaptations. Aortocaval compression by the gravid uterus reduces venous return by 30% - 50%, while the 40% - 50% increase in cardiac output during pregnancy creates a precarious hemodynamic balance [9][10]. The enlarged uterus displaces the inferior vena cava, compromising venous return, particularly in the supine position, despite left lateral tilt positioning [11].

Neurohormonal factors further compound this vulnerability. Pregnancy-induced changes in autonomic nervous system sensitivity, increased plasma volume (45% - 50% above non-pregnant values), and altered baroreceptor responsiveness create a perfect storm for profound hypotension following sympathetic blockade [12][13]. The rapid onset of spinal anesthesia (within 5 - 10 minutes) leaves insufficient time for compensatory mechanisms to activate, resulting in the characteristic precipitous blood pressure drop observed in 70% - 80% of parturients [14].

The evolution of vasopressor therapy for post-spinal hypotension reflects our growing understanding of maternal-fetal physiology and drug pharmacology. Traditional management relied heavily on fluid preloading and ephedrine as the vasopressor of choice, based on animal studies suggesting preserved uteroplacental blood flow [15][16].

Ephedrine(Mixedα/β-agonist): Long considered the gold standard, ephedrine acts indirectly by releasing endogenous norepinephrine and directly stimulating α and β-adrenergic receptors [17]. Its appeal stemmed from the theoretical maintenance of uteroplacental perfusion through combined inotropic and vasoconstrictive effects. However, the landmark Cooper study (2002) demonstrated increased fetal acidosis compared to phenylephrine, challenging this paradigm [13].

Phenylephrine(Pureα1-agonist): Emerged as the preferred alternative following concerns about ephedrine-induced fetal acidosis. Its pure α1-adrenergic action provides predictable vasoconstriction without direct fetal effects [18][19]. However, phenylephrine’s limitation lies in its potential to cause reflex bradycardia and reduced cardiac output, particularly problematic in patients with limited cardiac reserve [20][21].

Norepinephrine(Balancedα1/β1-agonist): Represents the newest addition to the obstetric vasopressor armamentarium. As an endogenous catecholamine, norepinephrine combines predominant α1-adrenergic activity (vasoconstriction) with moderate β1-adrenergic effects (positive inotropy), theoretically offering optimal hemodynamic balance [22][23].

Alternativeapproaches: vasopressin analogs, angiotensin II, and combination therapies, though these remain investigational in obstetric practice [24][25].

Low-dose norepinephrine has emerged as a promising therapeutic option, addressing the limitations of both ephedrine and phenylephrine while maintaining an excellent safety profile [26][27]. The rationale for low-dose norepinephrine stems from its unique pharmacological properties and physiological compatibility with pregnancy-induced cardiovascular changes.

Pharmacologicaladvantages: Norepinephrine’s balanced receptor profile (α1:β1 ratio approximately 3:1) provides vasoconstriction without excessive chronotropic effects [28]. Unlike ephedrine’s indirect action requiring endogenous catecholamine stores, norepinephrine acts directly and predictably. Compared to phenylephrine’s pure α1-agonism, norepinephrine’s β1-activity maintains cardiac contractility and prevents reflex bradycardia [29][30].

Dosingconsiderations: Low-concentration preparations (8 - 16 μg/mL) allow precise titration and reduce the risk of hypertensive episodes. This concentration range provides effective vasoconstriction while minimizing β-adrenergic overstimulation, crucial in the hemodynamically sensitive obstetric population [31][32].

Clinicalevidence: Recent studies demonstrate norepinephrine’s superiority in maintaining hemodynamic stability, reducing maternal side effects, and achieving faster blood pressure recovery compared to traditional agents [33][34]. The 2024 network meta-analysis by Zhang etal. confirmed norepinephrine’s optimal risk-benefit profile across multiple outcomes [18].

Table 3. Principal comparative studies in vasopressor management (2019-2024).

RCT: Randomized Controlled Trial; MA: Meta-Analysis; NE: Norepinephrine; PE: Phenylephrine; Eph: Ephedrine; Proph: Prophylactic; Ther: Therapeutic.

The choice between continuous infusion and bolus administration of norepinephrine represents a critical decision point in clinical practice, each approach offering distinct advantages and limitations (Table 4) [35].

Clinical Synthesis: Our study results align with this comparative analysis, demonstrating 94% efficacy with continuous infusion versus 89% with bolus administration. While continuous infusion achieved superior prevention rates and hemodynamic stability, bolus administration offers practical advantages in terms of simplicity, cost-effectiveness, and ease of implementation [36][37].

Recommendation Framework: Continuous infusion may be reserved for high-risk patients, teaching institutions, or centers with dedicated obstetric anesthesia teams, while bolus administration remains appropriate for standard clinical practice and resource-limited settings.

Table 4. Comparative analysis: continuous infusion vs bolus norepinephrine.

Our findings support a tiered approach to vasopressor selection in obstetric anesthesia. Low-dose norepinephrine, whether administered as a bolus or continuous infusion, demonstrates clear superiority over ephedrine and represents a significant advancement in maternal-fetal care. The choice between administration modalities should be individualized based on patient risk factors, institutional resources, and clinical expertise [38].

The paradigm shift toward norepinephrine-based protocols reflects evidence-based evolution in obstetric anesthesia, prioritizing both maternal hemodynamic stability and neonatal safety while improving overall patient experience and satisfaction.

Several limitations must be acknowledged. The single-center design may limit generalizability, although our institution’s high volume and standardized protocols enhance the validity of the results. The relatively short follow-up period precludes assessment of long-term outcomes.

The absence of blinding represents a significant limitation due to different administration modalities (bolus versus continuous infusion). However, objective hemodynamic parameters remain unaffected by this limitation, and blinding was not feasible given the distinct protocols requiring different preparation and administration techniques.

Arrhythmiaandadverseeventmonitoring: While continuous cardiac rhythm monitoring was performed throughout the procedure using standard 3-lead ECG, we did not use advanced arrhythmia detection algorithms or 24-hour Holter monitoring, which might have detected subtle rhythm disturbances or delayed arrhythmogenic effects. Other catecholamine-related adverse events, such as peripheral vasoconstriction, anxiety, or tremor, were assessed clinically but not using standardized, validated scales, representing another limitation in our comprehensive safety evaluation.

Generalizabilityconcerns: Our study was conducted in a single tertiary care center with experienced anesthesiologists, which may limit the applicability of results to centers with different expertise levels or patient populations.

Our results open several research avenues. Optimal norepinephrine dosing requires further investigation, particularly for prophylactic infusion protocols. Cost-effectiveness analyses would inform healthcare policy decisions.

Long-term neonatal follow-up studies would provide additional safety data. Investigation of norepinephrine efficacy in high-risk obstetric populations (preeclampsia, cardiac disease) represents another important research direction.